Key Takeaways Edwards Lifesciences sees growth in Surgical Structural Heart, led by RESILIA tissue adoption.EW's TAVR and TMTT segments posted strong Q3 gains supported by new approvals and global rollouts.Macro pressures, higher COGS and ongoing litigation continue to challenge Edwards' profitability.Edwards Lifesciences Corporation (EW) is well-poised to grow in the coming quarters owing to its Surgical Structural Heart, which pioneered the RESILIA tissue. The company’s Transcatheter Aortic Valve Replacem ...